{
  "report_rows": [
    {
      "kpi": "Q2 revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$6.130B vs. cons $6.096B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 operating EPS",
      "prediction": "BEAT",
      "answer": "pred ~$1.860 vs. cons $1.838",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 Biotechnology revenue",
      "prediction": "BEAT",
      "answer": "pred ~$1.990B vs. cons $1.962B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY26 core growth",
      "prediction": "BETTER",
      "answer": "guide 3%-6% vs. cons 2.93%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 adjusted EPS",
      "prediction": "UNCHANGED",
      "answer": "guide $8.35-$8.55 vs. cons $8.458",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q3 formal guide",
      "prediction": "UNKNOWN",
      "answer": "UNVERIFIED",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": -2.0,
  "day1_confidence": "LOW",
  "day5_residual_pct": -3.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 maintained FY framework implies softer out-period estimates",
  "day5_confidence": "LOW"
}